TRIB3 and neoplasm: SAH-JGZ4 administration inhibited tumor growth of NCI-H460 cells but not NCI-H157 and NCI-H2170 cells (Supplementary Fig. 8d–f), suggesting that tumors with high expression of both TRIB3 and EGFR would be sensitive to SAH-JGZ4 treatment.